Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
80 hedge funds and large institutions have $379M invested in Oyster Point Pharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 12 closing their positions.
397% more call options, than puts
Call options by funds: $2.25M | Put options by funds: $452K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
80% more capital invested
Capital invested by funds: $211M → $379M (+$168M)
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
16% more funds holding
Funds holding: 69 → 80 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.3M |
| 2 |
CAC
Cowen and Company
New York
|
+$6.47M |
| 3 |
RI
RTW Investments
New York
|
+$2.5M |
| 4 |
SCM
Sio Capital Management
New York
|
+$2.31M |
| 5 |
First Manhattan
New York
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$7.58M |
| 2 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$1.17M |
| 3 |
Renaissance Technologies
New York
|
-$1.11M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$586K |
| 5 |
Morgan Stanley
New York
|
-$573K |
OYST Hedge Fund Activity: Q4 2021 in Review
80 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q4 2021, worth a combined $379M — up 80% from $211M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new OYST positions and 12 closed out — a net gain of 11 holders — while 22 added to existing stakes and 16 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $20.3M. The largest seller was Vida Ventures Advisors, exiting entirely with an estimated $7.58M sold.
- 80 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q4 2021, up from 69 in Q3 2021.
- Funds reported $379M of Oyster Point Pharma, Inc. Common Stock stock for Q4 2021, up 80% quarter-over-quarter.
- 23 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q4 2021 and 12 closed out, a net change of +11 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q4 2021 was Point72 Asset Management, an estimated $20.3M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q4 2021 was Vida Ventures Advisors, an estimated $7.58M sold.
Based on aggregated 13F filings for Q4 2021.